Published in J Clin Densitom on January 01, 2003
Risk factors for hip fracture in older home care clients. J Gerontol A Biol Sci Med Sci (2009) 2.15
Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int (2008) 1.68
Assessing response to osteoporosis therapy. Osteoporos Int (2008) 0.95
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. Osteoporos Int (2014) 0.85
Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials. Osteoporos Int (2016) 0.75
Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2011) 23.10
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
Predictive value of BMD for hip and other fractures. J Bone Miner Res (2005) 6.46
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet (2002) 3.00
Trends in hip fracture rates in Canada. JAMA (2009) 2.95
A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res (2004) 2.92
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Vitamin D insufficiency in a population of healthy western Canadians. CMAJ (2002) 2.73
Muscle weakness and falls in older adults: a systematic review and meta-analysis. J Am Geriatr Soc (2004) 2.71
The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell (2004) 2.65
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2008) 2.57
Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. J Bone Miner Res (2015) 2.52
A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med (2004) 2.48
Measurement properties of the neck disability index: a systematic review. J Orthop Sports Phys Ther (2009) 2.47
Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab (2012) 2.41
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Alcohol intake as a risk factor for fracture. Osteoporos Int (2004) 2.34
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Postmenopausal women with osteopenia have higher cortical porosity and thinner cortices at the distal radius and tibia than women with normal aBMD: an in vivo HR-pQCT study. J Bone Miner Res (2010) 2.34
Mortality in patients with necrotizing fasciitis. Plast Reconstr Surg (2007) 2.25
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res (2010) 2.20
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 2.16
Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res (2004) 2.15
Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15
Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int (2004) 2.09
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
A systematic review and meta-analysis of studies using the STRATIFY tool for prediction of falls in hospital patients: how well does it work? Age Ageing (2008) 1.94
Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids. J Allergy Clin Immunol (2006) 1.93
The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 1.92
Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol (2009) 1.90
Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT study. J Bone Miner Res (2011) 1.86
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab (2011) 1.81
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res (2010) 1.74
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol (2009) 1.70
Computerized clinical decision support systems for chronic disease management: a decision-maker-researcher partnership systematic review. Implement Sci (2011) 1.70
Diagnosis and management of vertebral fractures in elderly adults. Am J Med (2002) 1.68
Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom (2008) 1.66
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Exercise for improving outcomes after osteoporotic vertebral fracture. Cochrane Database Syst Rev (2013) 1.63
Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med (2007) 1.63
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Effect of low-intensity pulsed ultrasound on the cartilage repair in people with mild to moderate knee osteoarthritis: a double-blinded, randomized, placebo-controlled pilot study. Arch Phys Med Rehabil (2012) 1.60
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada (summary). CMAJ (2010) 1.59
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. BMJ Open (2013) 1.55
Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol (2008) 1.55
Meta-analysis of the quantity of calcium excretion associated with the net acid excretion of the modern diet under the acid-ash diet hypothesis. Am J Clin Nutr (2008) 1.55
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am (2012) 1.54
A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol (2004) 1.54
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res (2010) 1.54
Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Educ Couns (2002) 1.53
Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev (2002) 1.53
A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract (2011) 1.50
References to anesthesia, pain, and analgesia in the Hippocratic Collection. Anesth Analg (2009) 1.48
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res (2006) 1.48
The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord (2002) 1.47
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause (2013) 1.47
A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause (2015) 1.45
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.44
A prospective study of tumor and technical factors associated with positive margins in breast-conservation therapy for nonpalpable malignancy. Am J Surg (2012) 1.44
The Canadian Rheumatology Association/ Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. J Rheumatol (2007) 1.44
Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging (2007) 1.44